Ciara M.
- Country
- Ireland
- Department
- Paediatric Endocrinology & Diabetes
Research Overview
- Efficacy and Safety Evaluation of Navepegritide and Lonapegsomatropin in Pediatric Achondroplasia: A 156-Week, Phase 2, Open-Label, Single-Arm Study
- Phase 2 Multicenter Double-Blind Randomized Placebo-Controlled Trial of TransCon CNP in Infants with Achondroplasia Evaluating Safety, Tolerability, and Efficacy
- Evaluation of Efficacy and Safety of Subcutaneous Navepegritide in Adolescents with Achondroplasia: A Phase 2b Randomized, Double-Blind, Placebo-Controlled Trial
Data & Insights
Has run more than one trial at 6 of 15 partner sites.
Specializations
Pediatric Growth Disorders
This investigator specializes in treating achondroplasia in children and adolescents, focusing on innovative therapeutic approaches for skeletal growth disorders.
- Growth pattern evaluation
- Skeletal development monitoring
- Long-term therapeutic management
Their research encompasses comprehensive evaluation of growth patterns in pediatric patients with skeletal dysplasia.
Therapeutic Innovation
The investigator studies novel therapeutic compounds including navepegritide and lonapegsomatropin for treating growth disorders.
- Growth stimulation therapies
- Combined treatment approaches
- Weekly administration protocols
Their work involves evaluating innovative treatment protocols for optimizing growth outcomes in pediatric patients.
Clinical Safety Assessment
The investigator focuses on evaluating the safety and tolerability of growth-promoting treatments in pediatric populations.
- Long-term safety monitoring
- Treatment tolerability assessment
- Therapeutic efficacy evaluation
Their expertise includes comprehensive safety assessment of growth-promoting therapies in developing children.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.